Pharmacyclic’s Imbruvica Beats GSK’s Arzerra in Elderly CLL Patients | PharmaBoardroom
written on 19.06.2014
Tags:
,

Pharmacyclic’s Imbruvica Beats GSK’s Arzerra in Elderly CLL Patients

TAGS: ,

As the American Society of Clinical Oncology (ASCO) meeting entered day two, coffee-sipping attendees perked to a first-in-the-morning discussion of the phase III data with Pharmacyclics Inc.’s ibrutinib (branded Imbruvica) in relapsed chronic lymphocytic leukemia (CLL), the first time an oral drug has yielded survival improvement over standard therapy. CLL is usually treated with chemo-immunotherapy, […]

Latest Report